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This content is made available for your personal use, educational advancement, or professional development. Unauthorized reproduction is prohibited. For permission to re-use for commercial or other purposes, please contact permissions@asco.org chemotherapy, with 26% requiring dose reductions (Table) . Overall, of the 9/16 (56.3%) patients who progressed within 6m of completing docetaxel, 3 had Cabazitaxel as the next treatment (P: 2/3 (66.7%), median PFS 6.2m) and 6 had novel androgen receptor targeted therapy (P: 5/6 (83.3%), median PFS 3.3m).
Conclusions:
Upfront docetaxel is reasonably well tolerated in the elderly with comparable median PFS to younger patients. Use of GCSF signi cantly minimizes the risk of FN in this group and should be considered as standard of care. In patients who progress within 6m of completing docetaxel, we feel optimal sequencing to be Cabazitaxel followed by subsequent therapies.
Elderly (%) Non-elderly (%) N 17 (45) 21 (55) 
